Hints and tips:
Related Special Reports
Related Topics
...Despite Novo Nordisk and Eli Lilly’s lead, Steensberg believed there was space for others to develop weight-loss products....
...But the companies do not have a history of protein manufacturing used by Novo Nordisk and its US rival Eli Lilly to make their diabetes and weight-loss products....
...The push into prescriptions and drug delivery is unusual for a pharmaceutical manufacturer, pitting Eli Lilly against pharmacies such as CVS and Walgreens....
...The push into prescriptions and drug delivery is unusual for a pharmaceutical manufacturer, pitting Eli Lilly against US pharmacy chains such as CVS and Walgreens. Read more here...
...But that is what Eli Lilly did this week....
...US drug regulators have delayed a decision on whether to approve Eli Lilly’s breakthrough Alzheimer’s drug, which was expected to be greenlit this month, the drugmaker said on Friday....
...Patients on the donanemab study had more advanced Alzheimer’s than patients on similar studies, Eli Lilly said....
...BSP previously produced Covid antibody treatment bamlanivimab for Eli Lilly....
...Eli Lilly was once considered something of an also-ran in the pharmaceutical industry....
...Demand for a new class of diabetes and obesity drugs will boost US drugmaker Eli Lilly’s sales by 20 per cent in 2024, pushing its revenues above $40bn, the company said on Tuesday....
...It is also unlikely that Eli Lilly will provide enough doses of the drug to Britain to meet the demand for weight loss treatments....
...Eli Lilly has called for competition regulators to scrutinise an $11bn deal by its main competitor Novo Nordisk to snap up additional manufacturing capacity, as the rivalry between the drugmakers to dominate...
...Eli Lilly’s share price fell as much as 2.4 per cent in early US trading before later recovering its losses....
...The US federal drug regulator has approved Eli Lilly’s injectable diabetes medication for weight loss, as demand for the blockbuster treatments continues to surge....
...Eli Lilly lowered its expectations for full-year earnings because of accounting charges related to recent acquisitions, despite beating expectations in the third quarter driven by growth in diabetes and...
...The side effects of Eli Lilly’s and Novo Nordisk’s obesity treatments are very similar, and patients could switch from one to the other, Stanford said....
...“The obesity field is going to be dominated by those two guys [Novo Nordisk and Eli Lilly] and who wants to go up against them?” he said. “It would be super hard.”...
...Eli Lilly’s $12.50 a share cash offer for Point represents a 50 per cent premium to the stock’s undisturbed three month average....
...Eli Lilly, the world’s largest drugmaker, plans to bolster its portfolio of cancer drugs by buying Point Biopharma for $1.4bn, paying a premium of almost 90 per cent to Monday’s closing price....
...Eli Lilly has agreed to buy cancer biotech Point Biopharma for about $1.4bn, paying a premium of almost 90 per cent to Monday’s closing price amid a severe cash crunch in the biotech industry....
...Eli Lilly also reported positive phase II results for the treatment of MASH this month, while Novo Nordisk’s Wegovy is in late stage trials for the disease area....
...Both Leqembi and Eli Lilly’s new drug donanemab target amyloid, a toxic protein that builds up in the brain, usually before significant levels of tau develop....
...US drugmaker Eli Lilly is riding a wave of investor optimism and media hype about new treatments for two of the biggest public health problems: obesity and Alzheimer’s....
...Eli Lilly shares hit a record high after the pharmaceuticals group upgraded its 2023 revenue and profit forecasts following a surge in sales of its new diabetes and weight-loss drug Mounjaro....
...Second-quarter results from Eli Lilly showed how quickly demand is increasing....
International Edition